Anti-CALU Polyclonal Antibody

Catalog No.

PHA80201

Species reactivity

Human, Mouse, Rat

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Human CALU (Lys20-Phe315).

Tested applications

ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000

Target

Crocalbin,CALU,Calumenin,IEF SSP 9302

Purification

Purified by antigen affinity column.

Accession

O43852

Applications

ELISA, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Entry Efficiency, Protease Dependence, and Antibody-Mediated Neutralization of SARS-CoV-2 Sublineages KP.3.1.1 and XEC., PMID:40333265

Neutralization and spike stability of JN.1-derived LB.1, KP.2.3, KP.3, and KP.3.1.1 subvariants., PMID:40136024

Complement-mediated enhancement of SARS-CoV-2 antibody neutralisation potency in vaccinated individuals., PMID:40102474

Fabrication of Bioconjugates Clacked Chitosan-Coated SN-38 Liposomal Nanoparticles: Improved Precise Chemotherapy Efficacy in Lung Cancer Cells and Its Apoptosis., PMID:40069999

Development and application of a high-titer VSV-based HCoV-NL63 pseudovirus system via C-terminal 14 amino acid truncation of spike., PMID:39922054

Comparative Analysis of Host Cell Entry Efficiency and Neutralization Sensitivity of Emerging SARS-CoV-2 Lineages KP.2, KP.2.3, KP.3, and LB.1., PMID:39591139

SARS-CoV-2-Specific T-Cell as a Potent Therapeutic Strategy against Immune Evasion of Emerging COVID-19 Variants., PMID:39408840

Neutralization and Stability of JN.1-derived LB.1, KP.2.3, KP.3 and KP.3.1.1 Subvariants., PMID:39282390

Beyond its preferential niche: Brucella abortus RNA down-modulates the IFN-γ-induced MHC-I expression in epithelial and endothelial cells., PMID:38980867

SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1., PMID:38779718

Lipid Nanoparticle-Based Inhibitors for SARS-CoV-2 Host Cell Infection., PMID:38562613

Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antivirals., PMID:38548023

[Persistent Polyclonal B-Cell Lymphocytosis (PPBL): An Entity That Is Not What it Seems]., PMID:38470949

Glycan-directed SARS-CoV-2 inhibition by leek extract and lectins with insights into the mode-of-action of Concanavalin A., PMID:38447646

Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants., PMID:38194968

SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency., PMID:38194966

Analysis of spike protein variants evolved in a novel in vivo long-term replication model for SARS-CoV-2., PMID:38029235

Characterization of intrinsic and effective fitness changes caused by temporarily fixed mutations in the SARS-CoV-2 spike E484 epitope and identification of an epistatic precondition for the evolution of E484A in variant Omicron., PMID:37940989

Reconstituted dry powder formulations of ZnO-adjuvanted ovalbumin induce equivalent antigen specific antibodies but lower T cell responses than ovalbumin adjuvanted with Alhydrogel® or cationic adjuvant formulation 01 (CAF®01)., PMID:37931728

The Apolipoprotein E neutralizing antibody inhibits SARS-CoV-2 infection by blocking cellular entry of lipoviral particles., PMID:37822714

Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3., PMID:37819267

Characteristics and functions of infection-enhancing antibodies to the N-terminal domain of SARS-CoV-2., PMID:37786672

Immune Evasion, Infectivity, and Fusogenicity of SARS-CoV-2 Omicron BA.2.86 and FLip Variants., PMID:37745517

In Vitro Analysis of the Effect of SARS-CoV-2 Non-VOC and four Variants of Concern on MHC-Class-I Expression on Calu-3 and Caco-2 Cells., PMID:37510253

The effects of cetuximab and cisplatin anti-cancer drugs on the mechanical properties of the lung cancerous cells using atomic force microscope., PMID:37437307

HLA-E-restricted SARS-CoV-2-specific T cells from convalescent COVID-19 patients suppress virus replication despite HLA class Ia down-regulation., PMID:37390223

Neutralization escape of Omicron XBB, BR.2, and BA.2.3.20 subvariants., PMID:37148877

Discovery of Highly Potent Small Molecule Pan-Coronavirus Fusion Inhibitors., PMID:37112982

Plasmacytoid dendritic cells stimulated with Lactococcus lactis strain Plasma produce soluble factors to suppress SARS-CoV-2 replication., PMID:37094430

SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors., PMID:36890632

PD-L1/PD-1 blockage enhanced the cytotoxicity of natural killer cell on the non-small cell lung cancer (NSCLC) by granzyme B secretion., PMID:36856921

Antiviral Activity of Micafungin and Its Derivatives against SARS-CoV-2 RNA Replication., PMID:36851666

BA.1, BA.2 and BA.2.75 variants show comparable replication kinetics, reduced impact on epithelial barrier and elicit cross-neutralizing antibodies., PMID:36827451

Extracellular vesicles mediate antibody-resistant transmission of SARS-CoV-2., PMID:36609376

Cold-adapted SARS-CoV-2 variants with different temperature sensitivity exhibit an attenuated phenotype and confer protective immunity., PMID:36528447

Identification of a pharmacological approach to reduce ACE2 expression and development of an in vitro COVID-19 viral entry model., PMID:36514715

Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics., PMID:36503013

Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2., PMID:36476380

Induction of significant neutralizing antibodies against SARS-CoV-2 by a highly attenuated pangolin coronavirus variant with a 104nt deletion at the 3'-UTR., PMID:36453209

Adding of neurotensin to non-small cell lung cancer cells increases tyrosine phosphorylation of HER3., PMID:35932909

Human lung-cancer-cell radioresistance investigated through 2D network topology., PMID:35902618

Proper Selection of In Vitro Cell Model Affects the Characterization of the Neutralizing Antibody Response against SARS-CoV-2., PMID:35746703

Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct., PMID:35737747

SARS-CoV-2 Variants of Concern Hijack IFITM2 for Efficient Replication in Human Lung Cells., PMID:35543509

Replication kinetics and infectivity of SARS-CoV-2 variants of concern in common cell culture models., PMID:35473640

SARS-CoV-2 Omicron spike mediated immune escape and tropism shift., PMID:35075452

Immunological Characterization of HIV and SARS-CoV-2 Coinfected Young Individuals., PMID:34831410

Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination., PMID:34818119

A Potential Role of the CD47/SIRPalpha Axis in COVID-19 Pathogenesis., PMID:34698067

Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization., PMID:34645933

Document Download

Anti-CALU Polyclonal Antibody.pdf